CN105601735A - 一种静注巨细胞人免疫球蛋白及其制备方法 - Google Patents
一种静注巨细胞人免疫球蛋白及其制备方法 Download PDFInfo
- Publication number
- CN105601735A CN105601735A CN201610060338.5A CN201610060338A CN105601735A CN 105601735 A CN105601735 A CN 105601735A CN 201610060338 A CN201610060338 A CN 201610060338A CN 105601735 A CN105601735 A CN 105601735A
- Authority
- CN
- China
- Prior art keywords
- liquid
- hig
- protein
- filtration
- human immunoglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 69
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 69
- 238000002360 preparation method Methods 0.000 title claims abstract description 39
- 241000701022 Cytomegalovirus Species 0.000 title claims abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 93
- 238000001914 filtration Methods 0.000 claims abstract description 63
- 241000700605 Viruses Species 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 40
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 33
- 101000623895 Bos taurus Mucin-15 Proteins 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 11
- 238000011084 recovery Methods 0.000 claims abstract description 10
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 8
- 238000011534 incubation Methods 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 230000002779 inactivation Effects 0.000 claims abstract description 6
- 239000002120 nanofilm Substances 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims description 113
- 210000004027 cell Anatomy 0.000 claims description 104
- 210000002381 plasma Anatomy 0.000 claims description 82
- 239000000243 solution Substances 0.000 claims description 80
- 102000004169 proteins and genes Human genes 0.000 claims description 76
- 108090000623 proteins and genes Proteins 0.000 claims description 76
- 238000001556 precipitation Methods 0.000 claims description 54
- 238000012423 maintenance Methods 0.000 claims description 33
- 238000006386 neutralization reaction Methods 0.000 claims description 32
- 238000012360 testing method Methods 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 239000000376 reactant Substances 0.000 claims description 28
- 238000000926 separation method Methods 0.000 claims description 27
- 238000003756 stirring Methods 0.000 claims description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 24
- 238000010790 dilution Methods 0.000 claims description 24
- 239000012895 dilution Substances 0.000 claims description 24
- 238000004448 titration Methods 0.000 claims description 23
- 230000003612 virological effect Effects 0.000 claims description 23
- 239000008215 water for injection Substances 0.000 claims description 23
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 22
- 239000006285 cell suspension Substances 0.000 claims description 20
- 238000011085 pressure filtration Methods 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 239000006228 supernatant Substances 0.000 claims description 17
- 238000000502 dialysis Methods 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 16
- 238000001816 cooling Methods 0.000 claims description 15
- 230000009849 deactivation Effects 0.000 claims description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 12
- 239000004471 Glycine Substances 0.000 claims description 11
- 239000013642 negative control Substances 0.000 claims description 11
- 238000010998 test method Methods 0.000 claims description 11
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 10
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 238000010612 desalination reaction Methods 0.000 claims description 10
- 238000011068 loading method Methods 0.000 claims description 10
- 238000005352 clarification Methods 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 7
- 230000007935 neutral effect Effects 0.000 claims description 7
- 238000009928 pasteurization Methods 0.000 claims description 7
- 239000008363 phosphate buffer Substances 0.000 claims description 7
- 239000003643 water by type Substances 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 230000012447 hatching Effects 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 6
- 239000013049 sediment Substances 0.000 claims description 6
- 208000020061 Hand, Foot and Mouth Disease Diseases 0.000 claims description 5
- 208000025713 Hand-foot-and-mouth disease Diseases 0.000 claims description 5
- 229920005654 Sephadex Polymers 0.000 claims description 5
- 239000012507 Sephadex™ Substances 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 230000029087 digestion Effects 0.000 claims description 5
- 238000011049 filling Methods 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 239000003223 protective agent Substances 0.000 claims description 5
- 238000007790 scraping Methods 0.000 claims description 5
- 239000011265 semifinished product Substances 0.000 claims description 5
- 230000003068 static effect Effects 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 239000005723 virus inoculator Substances 0.000 claims description 5
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 claims description 4
- 230000005611 electricity Effects 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 102000006395 Globulins Human genes 0.000 claims description 3
- 108010044091 Globulins Proteins 0.000 claims description 3
- 238000005349 anion exchange Methods 0.000 claims description 3
- 239000000539 dimer Substances 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 239000012898 sample dilution Substances 0.000 claims description 2
- 238000005070 sampling Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 239000012295 chemical reaction liquid Substances 0.000 claims 1
- -1 makeIn goods Chemical compound 0.000 claims 1
- 230000008901 benefit Effects 0.000 abstract description 12
- 208000015181 infectious disease Diseases 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000003472 neutralizing effect Effects 0.000 abstract description 3
- 238000003825 pressing Methods 0.000 abstract description 2
- 238000004440 column chromatography Methods 0.000 abstract 1
- 238000005342 ion exchange Methods 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 31
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 17
- 239000002609 medium Substances 0.000 description 17
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000007170 pathology Effects 0.000 description 12
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- 230000003750 conditioning effect Effects 0.000 description 7
- 238000003860 storage Methods 0.000 description 6
- 239000008351 acetate buffer Substances 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000005571 anion exchange chromatography Methods 0.000 description 4
- 239000012930 cell culture fluid Substances 0.000 description 4
- 239000012501 chromatography medium Substances 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 102000011759 adducin Human genes 0.000 description 3
- 108010076723 adducin Proteins 0.000 description 3
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 208000006379 syphilis Diseases 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 101100459439 Caenorhabditis elegans nac-2 gene Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010027906 Monocytosis Diseases 0.000 description 1
- 108090000113 Plasma Kallikrein Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000037890 multiple organ injury Diseases 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/088—Varicella-zoster virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
检测项目 | A(普通血浆) | B(高低度特异性血浆) |
蛋白含量 | 56.5g/L | 57.5g/L |
HCMV中和抗体效价 | 1:20 | 1:175 |
检测项目 | A(普通血浆) | B(高低度特异性血浆) |
蛋白含量 | 56g/L | 56.5g/L |
HCMV中和抗体效价 | 1:26 | 1:165 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610060338.5A CN105601735B (zh) | 2016-01-28 | 2016-01-28 | 一种静注巨细胞人免疫球蛋白及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610060338.5A CN105601735B (zh) | 2016-01-28 | 2016-01-28 | 一种静注巨细胞人免疫球蛋白及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105601735A true CN105601735A (zh) | 2016-05-25 |
CN105601735B CN105601735B (zh) | 2019-04-19 |
Family
ID=55982141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610060338.5A Active CN105601735B (zh) | 2016-01-28 | 2016-01-28 | 一种静注巨细胞人免疫球蛋白及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105601735B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107090026A (zh) * | 2017-03-27 | 2017-08-25 | 武汉中原瑞德生物制品有限责任公司 | 利用硅藻土从血液制品中分离血浆蛋白的方法和系统 |
CN110256556A (zh) * | 2019-06-28 | 2019-09-20 | 成都欧林生物科技股份有限公司 | 一种耐甲氧西林金黄色葡萄球菌人免疫球蛋白及制备方法 |
CN112225799A (zh) * | 2020-10-19 | 2021-01-15 | 英科博雅基因科技(天津)有限公司 | 自动化分离系统快速提取covid-19患者康复期血浆的方法 |
CN115389291A (zh) * | 2022-10-26 | 2022-11-25 | 北京肿瘤医院(北京大学肿瘤医院) | 一种尿液微量蛋白的富集、纯化和保护方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101361973A (zh) * | 2008-09-24 | 2009-02-11 | 四川远大蜀阳药业股份有限公司 | 一种治疗水痘的药物及其制备方法 |
CN101591389A (zh) * | 2009-06-30 | 2009-12-02 | 同路生物制药有限公司 | 水痘-带状疱疹人免疫球蛋白及其制备方法以及其在制药物中的应用 |
CN102286099A (zh) * | 2011-08-05 | 2011-12-21 | 深圳市卫武光明生物制品有限公司 | 静注巨细胞病毒人免疫球蛋白及其制备方法 |
CN103554252A (zh) * | 2013-11-15 | 2014-02-05 | 同路生物制药股份有限公司 | 一种巨细胞人免疫球蛋白及其制备方法 |
-
2016
- 2016-01-28 CN CN201610060338.5A patent/CN105601735B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101361973A (zh) * | 2008-09-24 | 2009-02-11 | 四川远大蜀阳药业股份有限公司 | 一种治疗水痘的药物及其制备方法 |
CN101591389A (zh) * | 2009-06-30 | 2009-12-02 | 同路生物制药有限公司 | 水痘-带状疱疹人免疫球蛋白及其制备方法以及其在制药物中的应用 |
CN102286099A (zh) * | 2011-08-05 | 2011-12-21 | 深圳市卫武光明生物制品有限公司 | 静注巨细胞病毒人免疫球蛋白及其制备方法 |
CN103554252A (zh) * | 2013-11-15 | 2014-02-05 | 同路生物制药股份有限公司 | 一种巨细胞人免疫球蛋白及其制备方法 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107090026A (zh) * | 2017-03-27 | 2017-08-25 | 武汉中原瑞德生物制品有限责任公司 | 利用硅藻土从血液制品中分离血浆蛋白的方法和系统 |
CN110256556A (zh) * | 2019-06-28 | 2019-09-20 | 成都欧林生物科技股份有限公司 | 一种耐甲氧西林金黄色葡萄球菌人免疫球蛋白及制备方法 |
CN112225799A (zh) * | 2020-10-19 | 2021-01-15 | 英科博雅基因科技(天津)有限公司 | 自动化分离系统快速提取covid-19患者康复期血浆的方法 |
CN112225799B (zh) * | 2020-10-19 | 2022-08-16 | 英科博雅基因科技(天津)有限公司 | 自动化分离系统快速提取covid-19患者康复期血浆的方法 |
CN115389291A (zh) * | 2022-10-26 | 2022-11-25 | 北京肿瘤医院(北京大学肿瘤医院) | 一种尿液微量蛋白的富集、纯化和保护方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105601735B (zh) | 2019-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105601736B (zh) | 一种抗呼吸道合胞病毒人免疫球蛋白及其制备方法 | |
CN105601735A (zh) | 一种静注巨细胞人免疫球蛋白及其制备方法 | |
CN102178952B (zh) | 一种层析法提取破伤风人免疫球蛋白的方法 | |
CN111471103A (zh) | 一种新冠病毒(2019-nCOV)的异源抗体及其制备方法 | |
CN111393531A (zh) | 一种亚单位融合蛋白CD2V-Fc及其制备方法和应用 | |
CN111471089A (zh) | 一种重组的非洲猪瘟病毒cd2v亚单位蛋白及其制备方法和应用 | |
CN105669860B (zh) | 一种抗手足口病人免疫球蛋白及其制备方法 | |
CN102127164A (zh) | 一种从水稻种子中提取重组人血清白蛋白的方法 | |
CN103721249B (zh) | 一种流脑疫苗及其制备方法 | |
CN116731162B (zh) | 人免疫球蛋白生产工艺 | |
CN102180966B (zh) | 一种规模化生产人α1-抗胰蛋白酶的方法 | |
US20130172536A1 (en) | Intravenous Cytomegalovirus Human Immune Globulin and Manufacturing Method Thereof | |
CN101591393B (zh) | 一种狂犬病、破伤风双效价人免疫球蛋白及其制备方法以及其在制药物中的应用 | |
CN103554252B (zh) | 一种巨细胞人免疫球蛋白及其制备方法 | |
CN112010968A (zh) | 快速提取covid-19患者康复期血浆用于制备免疫球蛋白g的方法 | |
CN113603804B (zh) | 一种肺炎链球菌荚膜多糖的精制方法 | |
CN101361973A (zh) | 一种治疗水痘的药物及其制备方法 | |
CN110339351A (zh) | 一种兽用狂犬病灭活疫苗的制备方法及该疫苗包含的稳定剂 | |
CN101481692B (zh) | 无血清制备重组人类凝血因子ⅸ | |
CN101591391B (zh) | 肠道病毒71型人免疫球蛋白及其制备方法 | |
CN111166877A (zh) | 一种狂犬病人免疫球蛋白的制备方法 | |
CN1312292A (zh) | 从转基因抗菌肽蝇蛆中制备人用基因抗菌肽药品的方法 | |
CN103864926A (zh) | 一种双重病毒灭活制备狂犬人免疫球蛋白的方法 | |
CN106943588A (zh) | 热休克蛋白gp96在治疗银屑病中的应用 | |
CN102603891A (zh) | 一种双重病毒灭活制备破伤风人免疫球蛋白的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Yang Li Inventor after: Yu Yinhang Inventor after: Sun Xiaodong Inventor after: Yan Lei Inventor after: Sun Ting Inventor before: Yang Li Inventor before: Yu Yinhang Inventor before: Li Changlu Inventor before: Yang Jinping Inventor before: Chen Dongming Inventor before: Sun Xiaodong Inventor before: Yan Lei Inventor before: Sun Ting |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: No.77 Siping Road, Limin Economic Development Zone, Hulan District, Harbin City, Heilongjiang Province Patentee after: Harbin pesfico biopharmaceutical Co.,Ltd. Address before: No.77 Siping Road, Limin Economic Development Zone, Hulan District, Harbin City, Heilongjiang Province Patentee before: HARBIN PAISI FEIKE BIOLOGICAL PHARMACEUTICAL Co.,Ltd. |